Cabergoline in Parkinson's disease complicated by motor fluctuations

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Movement Disorders

• Publication date

  1996-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/MDS.870110504PMID 8866490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers.

  1994cited by this paper
• Multicenter study of cabergoline, a long‐acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa

  1993cited by this paper
• Controlled study of the antiparkinsonian activity and tolerability of cabergoline

  1993cited by this paper
• Cabergoline in Parkinson's disease

  1993cited by this paper
• Subcutaneous apomorphine in the treatment of Parkinson's disease.

  1990cited by this paper
• The promise and limitations of controlled-release oral levodopa administration.

  1989cited by this paper
• Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.

  1988cited by this paper
• PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSON'S DISEASE

  1981cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• On‐off response

  1975cited by this paper

• Medical treatment of the motor features of Parkinson disease

  2021cites this paper
• Definition and Classification of Parkinsonian Drugs

  2019cites this paper
• Initial management of Parkinson’s disease

  2014cites this paper
• Respiratory Dysfunction in Parkinson’s Disease

  2013cites this paper
• Toxicidad pleuropulmonar precoz asociada al tratamiento con cabergolina, un fármaco antiparkinsoniano

  2007cites this paper
• [Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].

  2007cites this paper
• Chapter 6 – Medical treatment of Parkinson disease

  2007cites this paper
• Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.

  2005cites this paper
• Subkutane Dauerinfusion mit Apomorphin

  2005cites this paper
• Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease.

  2005cites this paper
• Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five‐drug dose conversion table

  2004cites this paper
• Clinical Pharmacokinetics of Cabergoline

  2003cites this paper
• Dopamine agonists in Parkinson’s disease

  2003cites this paper
• Enone prodrugs of catecholamines

  2002cites this paper
• Management of Parkinson's disease: An evidence‐based review

  2002cites this paper
• DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease.

  2002cites this paper
• The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration

  2002cites this paper
• Respiratory Complications of Parkinson's Disease

  2002cites this paper
• Chapter 9 Clinical Trials in Parkinson's Disease

  2001cites this paper
• Apomorphine: An underutilized therapy for Parkinson's disease

  2000cites this paper
• Pergolide-Induced Dyspnea, Bilateral Pleural Effusion and Peripheral Edema

  2000cites this paper
• Dopamine agonists: the treatment for Parkinson's disease in the XXI century?

  2000cites this paper
• Pharmacotherapy for Advanced Parkinson's Disease

  2000influential citation
• Psychosis in Parkinson’s disease: ‘between a rock and a hard place’

  2000cites this paper
• [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].

  1999cites this paper
• Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.

  1999cites this paper
• Management of Parkinson's Disease: A Review of Current and New Therapies

  1999cites this paper
• Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide

  1999cites this paper
• Adjuncts to levodopa therapy

  1998cites this paper
• Prospects for new drug treatment in idiopathic parkinsonism

  1998cites this paper
• Cabergolin (Cabaseril®)

  1998cites this paper
• Medical treatment of Parkinson’s disease

  1998cites this paper
• The Treatment of Parkinson's Disease in Older People

  1997cites this paper